Session Type: ePosters
Session Title: ePosters
Authors(s): S.C. Uceda Renteria, A. Orlandi, C. Vigano, C. Melchionna, M. Oggioni
Authors Affiliations(s): Virology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Italy
Background:
We analyzed the macrolide and fluoroquinolone resistance in M. genitalium positive samples collected from symptomatic patients, attending an STI center in Milan (Italy) between March 2017 and October 2020.
Methods:A Total of 119 M. genitalium positive samples (72,3% males and 27,7% females), including 83 urethral swabs, 32 vaginal swabs and 4 anal swabs, were analyzed at the Virology Laboratory of the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
The samples were tested using two commercially-available multiplex qPCR assay (AllplexTM MG & AziR assay and AllplexTM MG & MoxiR assay, Seegene) for simultaneous detection of M. genitalium and point mutations associated with macrolide and fluoroquinolone resistance within the region V of the 23S rRNA gene and the quinolone resistance determining regions (QRDR) of parC respectively.
Furthermore, 99 samples were also analyzed with another commercial kit (ResistancePlus™ MG, Speedx) followed by sequence analysis with the Sanger method to evaluate clinical performance of new assay.
Results:From 119 M. genitalium positive specimens 63/119 (52,9%) and 18/119 (15,1%) resulted resistant to macrolide and fluoroquinolone resistance respectively. Interestingly, 14/119 (11,8%) positive specimen presented both azithromycin and moxifloxacin resistance.
The most common mutations of azithromycin resistance were A2059G (35/51, 68.6%) and A2058G (10/51, 19.6%), while the least frequent were A2058T (7/51, 13.7%) and the specimens resulted positive for moxifloxacin resistance presented a frequency of mutations of G259A (4/18, 22.2%), G248T (7/18, 38.9%), G259T (3/18, 16.7%), G248A (2/18, 11.1%), A247C (2/18, 11.1%).
Moreover, from 99 M. genitalium positive specimens tested with the ResistancePlusTM MG kit and MG & AziR assay, 52 (52.5%) and 51 (51.5%) resulted resistant to macrolide respectively. The presence of a single point mutation was confirmed in 51 of 52 samples with the Sanger Sequencing.
Conclusions:M.genitalium represents a significant sexually transmitted pathogen. The macrolide antibiotic azithromycin is still widely used for the treatment of M.genitalium infections in Milan, Italy. We provide evidence that macrolide resistance is also highly prevalent in M.genitalium in Milan. These results support that molecular diagnostic and the antibiotic resistance surveillance are strongly raccomended by the last European guideline on the management of M.genitalium infections.
Keyword(s): Mycoplasma genitalium, macrolide resistance, fluorochinolone resistanceSession Type: ePosters
Session Title: ePosters
Authors(s): S.C. Uceda Renteria, A. Orlandi, C. Vigano, C. Melchionna, M. Oggioni
Authors Affiliations(s): Virology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Italy
Background:
We analyzed the macrolide and fluoroquinolone resistance in M. genitalium positive samples collected from symptomatic patients, attending an STI center in Milan (Italy) between March 2017 and October 2020.
Methods:A Total of 119 M. genitalium positive samples (72,3% males and 27,7% females), including 83 urethral swabs, 32 vaginal swabs and 4 anal swabs, were analyzed at the Virology Laboratory of the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
The samples were tested using two commercially-available multiplex qPCR assay (AllplexTM MG & AziR assay and AllplexTM MG & MoxiR assay, Seegene) for simultaneous detection of M. genitalium and point mutations associated with macrolide and fluoroquinolone resistance within the region V of the 23S rRNA gene and the quinolone resistance determining regions (QRDR) of parC respectively.
Furthermore, 99 samples were also analyzed with another commercial kit (ResistancePlus™ MG, Speedx) followed by sequence analysis with the Sanger method to evaluate clinical performance of new assay.
Results:From 119 M. genitalium positive specimens 63/119 (52,9%) and 18/119 (15,1%) resulted resistant to macrolide and fluoroquinolone resistance respectively. Interestingly, 14/119 (11,8%) positive specimen presented both azithromycin and moxifloxacin resistance.
The most common mutations of azithromycin resistance were A2059G (35/51, 68.6%) and A2058G (10/51, 19.6%), while the least frequent were A2058T (7/51, 13.7%) and the specimens resulted positive for moxifloxacin resistance presented a frequency of mutations of G259A (4/18, 22.2%), G248T (7/18, 38.9%), G259T (3/18, 16.7%), G248A (2/18, 11.1%), A247C (2/18, 11.1%).
Moreover, from 99 M. genitalium positive specimens tested with the ResistancePlusTM MG kit and MG & AziR assay, 52 (52.5%) and 51 (51.5%) resulted resistant to macrolide respectively. The presence of a single point mutation was confirmed in 51 of 52 samples with the Sanger Sequencing.
Conclusions:M.genitalium represents a significant sexually transmitted pathogen. The macrolide antibiotic azithromycin is still widely used for the treatment of M.genitalium infections in Milan, Italy. We provide evidence that macrolide resistance is also highly prevalent in M.genitalium in Milan. These results support that molecular diagnostic and the antibiotic resistance surveillance are strongly raccomended by the last European guideline on the management of M.genitalium infections.
Keyword(s): Mycoplasma genitalium, macrolide resistance, fluorochinolone resistance
Session Type: ePosters
Session Title: ePosters
Authors(s): S.C. Uceda Renteria, A. Orlandi, C. Vigano, C. Melchionna, M. Oggioni
Authors Affiliations(s): Virology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Italy
Background:
We analyzed the macrolide and fluoroquinolone resistance in M. genitalium positive samples collected from symptomatic patients, attending an STI center in Milan (Italy) between March 2017 and October 2020.
Methods:A Total of 119 M. genitalium positive samples (72,3% males and 27,7% females), including 83 urethral swabs, 32 vaginal swabs and 4 anal swabs, were analyzed at the Virology Laboratory of the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
The samples were tested using two commercially-available multiplex qPCR assay (AllplexTM MG & AziR assay and AllplexTM MG & MoxiR assay, Seegene) for simultaneous detection of M. genitalium and point mutations associated with macrolide and fluoroquinolone resistance within the region V of the 23S rRNA gene and the quinolone resistance determining regions (QRDR) of parC respectively.
Furthermore, 99 samples were also analyzed with another commercial kit (ResistancePlus™ MG, Speedx) followed by sequence analysis with the Sanger method to evaluate clinical performance of new assay.
Results:From 119 M. genitalium positive specimens 63/119 (52,9%) and 18/119 (15,1%) resulted resistant to macrolide and fluoroquinolone resistance respectively. Interestingly, 14/119 (11,8%) positive specimen presented both azithromycin and moxifloxacin resistance.
The most common mutations of azithromycin resistance were A2059G (35/51, 68.6%) and A2058G (10/51, 19.6%), while the least frequent were A2058T (7/51, 13.7%) and the specimens resulted positive for moxifloxacin resistance presented a frequency of mutations of G259A (4/18, 22.2%), G248T (7/18, 38.9%), G259T (3/18, 16.7%), G248A (2/18, 11.1%), A247C (2/18, 11.1%).
Moreover, from 99 M. genitalium positive specimens tested with the ResistancePlusTM MG kit and MG & AziR assay, 52 (52.5%) and 51 (51.5%) resulted resistant to macrolide respectively. The presence of a single point mutation was confirmed in 51 of 52 samples with the Sanger Sequencing.
Conclusions:M.genitalium represents a significant sexually transmitted pathogen. The macrolide antibiotic azithromycin is still widely used for the treatment of M.genitalium infections in Milan, Italy. We provide evidence that macrolide resistance is also highly prevalent in M.genitalium in Milan. These results support that molecular diagnostic and the antibiotic resistance surveillance are strongly raccomended by the last European guideline on the management of M.genitalium infections.
Keyword(s): Mycoplasma genitalium, macrolide resistance, fluorochinolone resistanceSession Type: ePosters
Session Title: ePosters
Authors(s): S.C. Uceda Renteria, A. Orlandi, C. Vigano, C. Melchionna, M. Oggioni
Authors Affiliations(s): Virology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Italy
Background:
We analyzed the macrolide and fluoroquinolone resistance in M. genitalium positive samples collected from symptomatic patients, attending an STI center in Milan (Italy) between March 2017 and October 2020.
Methods:A Total of 119 M. genitalium positive samples (72,3% males and 27,7% females), including 83 urethral swabs, 32 vaginal swabs and 4 anal swabs, were analyzed at the Virology Laboratory of the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
The samples were tested using two commercially-available multiplex qPCR assay (AllplexTM MG & AziR assay and AllplexTM MG & MoxiR assay, Seegene) for simultaneous detection of M. genitalium and point mutations associated with macrolide and fluoroquinolone resistance within the region V of the 23S rRNA gene and the quinolone resistance determining regions (QRDR) of parC respectively.
Furthermore, 99 samples were also analyzed with another commercial kit (ResistancePlus™ MG, Speedx) followed by sequence analysis with the Sanger method to evaluate clinical performance of new assay.
Results:From 119 M. genitalium positive specimens 63/119 (52,9%) and 18/119 (15,1%) resulted resistant to macrolide and fluoroquinolone resistance respectively. Interestingly, 14/119 (11,8%) positive specimen presented both azithromycin and moxifloxacin resistance.
The most common mutations of azithromycin resistance were A2059G (35/51, 68.6%) and A2058G (10/51, 19.6%), while the least frequent were A2058T (7/51, 13.7%) and the specimens resulted positive for moxifloxacin resistance presented a frequency of mutations of G259A (4/18, 22.2%), G248T (7/18, 38.9%), G259T (3/18, 16.7%), G248A (2/18, 11.1%), A247C (2/18, 11.1%).
Moreover, from 99 M. genitalium positive specimens tested with the ResistancePlusTM MG kit and MG & AziR assay, 52 (52.5%) and 51 (51.5%) resulted resistant to macrolide respectively. The presence of a single point mutation was confirmed in 51 of 52 samples with the Sanger Sequencing.
Conclusions:M.genitalium represents a significant sexually transmitted pathogen. The macrolide antibiotic azithromycin is still widely used for the treatment of M.genitalium infections in Milan, Italy. We provide evidence that macrolide resistance is also highly prevalent in M.genitalium in Milan. These results support that molecular diagnostic and the antibiotic resistance surveillance are strongly raccomended by the last European guideline on the management of M.genitalium infections.
Keyword(s): Mycoplasma genitalium, macrolide resistance, fluorochinolone resistance